Drug Profile

ALT Q5

Alternative Names: ALT Q5; Q5-drug conjugate - Alteogen

Latest Information Update: 06 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alteogen
Class Antineoplastics; Drug conjugates; Immunotoxins
Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

06 Aug 2024 Discontinued - Preclinical for Ovarian cancer in South Korea (Parenteral)
28 Jun 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in South Korea (Parenteral)
27 May 2019 Preclinical trials in Ovarian cancer in South Korea (Parenteral) (Alteogen pipeline, May 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com